Oral application of 1,7-dimethylxanthine (paraxanthine) attenuates the formation of experimental cholestatic liver fibrosis. | Hepatol Res;41(11): 1094-109, 2011 Nov. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Subject descriptor lookup Advanced Search EVID@Easy

Oral application of 1,7-dimethylxanthine (paraxanthine) attenuates the formation of experimental cholestatic liver fibrosis.

Klemmer, Ildikó; Yagi, Shintaro; Gressner, Olav A.

Affiliation

Klemmer I; Wisplinghoff Medical Laboratories, Cologne, Germany Department of Hepatobiliary, Pancreas and Transplant Surgery, Kyoto University Hospital, Kyoto, Japan Institute for Laboratory Animal Science and Experimental Surgery Institute of Clinical Chemistry and Pathobiochemistry - Central Laboratory, RWTH- University Hospital, Aachen, Germany.

Hepatol Res ; 41(11): 1094-109, 2011 Nov.

Article in En | MEDLINE | ID: mdl-22032678

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Hepatol Res Year: 2011 Document type: Article Affiliation country: Germany Country of publication: Netherlands

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Hepatol Res Year: 2011 Document type: Article Affiliation country: Germany Country of publication: Netherlands